These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 30014145)

  • 1. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Nabulsi NB; Wyk BCV; Varma P; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2020 Jul; 16(7):974-982. PubMed ID: 32400950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Banks ER; Ni GS; Rogers K; Gallezot JD; Ropchan J; Emery PR; Nabulsi NB; Vander Wyk BC; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Neurobiol Aging; 2022 Mar; 111():44-53. PubMed ID: 34963063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Synaptic Density Imaging with
    Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
    J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET.
    Silva-Rudberg JA; Salardini E; O'Dell RS; Chen MK; Ra J; Georgelos JK; Morehouse MR; Melino KP; Varma P; Toyonaga T; Nabulsi NB; Huang Y; Carson RE; van Dyck CH; Mecca AP
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):17-28. PubMed ID: 37673749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An
    Li J; Huang Q; Qi N; He K; Li S; Huang L; Pan F; Ren S; Hua F; Huang Y; Guan Y; Guo Q; Zhao J; Xie F
    J Cereb Blood Flow Metab; 2024 Jul; 44(7):1199-1207. PubMed ID: 38295871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [
    Mecca AP; O'Dell RS; Sharp ES; Banks ER; Bartlett HH; Zhao W; Lipior S; Diepenbrock NG; Chen MK; Naganawa M; Toyonaga T; Nabulsi NB; Vander Wyk BC; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2022 Dec; 18(12):2527-2536. PubMed ID: 35174954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A; Scarpa M; Nordberg A
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic density in healthy human aging is not influenced by age or sex: a
    Michiels L; Delva A; van Aalst J; Ceccarini J; Vandenberghe W; Vandenbulcke M; Koole M; Lemmens R; Laere KV
    Neuroimage; 2021 May; 232():117877. PubMed ID: 33639258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
    Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.